摘要:
The invention relates to novel substituted piperidinyl-tetrahydroquinolines, methods for producing same, their use for treating and/or preventing diseases, and their use in the production of medications for treating and/or preventing diseases, particularly for treating and/or preventing diabetic microangiopathies, diabetic abscesses at extremities, particularly promoting tissue repair in diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart diseases, peripheral vascular and cardiovascular diseases, thromboembolic diseases and ischaemia, peripheral circulatory disorders, Raynaud's phenomenon, CREST syndrome, microcirculatory disorders, intermittent claudication, and peripheral and autonomic neuropathies.
摘要:
Die Erfindung betrifft Adrenorezeptor α2C Rezeptor Antagonisten zur Verwendung in einem Verfahren zur Behandlung und/oder Prophylaxe von Begleit- und/oder Folgeerkrankungen von Diabetes mellitus, diabetischen Herzerkrankungen, diabetischen koronaren Herzerkrankungen, diabetischen koronaren mikrovaskulären Herzerkrankungen, diabetischer Herzinsuffizienz, diabetischer Kardiomyopathie und Herzinfarkt, diabetischer Mikroangiopathie, diabetischer Retinopathie, diabetischer Neuropathie, diabetischer Nephropathie, diabetischer erektiler Dysfunktion, diabetischen Geschwüren an den Extremitäten, diabetischen Fußulzera, zur Förderung der diabetischen Wundheilung und zur Förderung der Wundheilung von diabetischen Fußulzera.
摘要:
The present invention relates to novel substituted piperidinyl-tetrahydroquinolines, to a method for the production thereof, to the use thereof for treating and/or preventing diseases, and to the use thereof for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for the promotion of wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular diseases of the heart, peripheral and cardiac vascular diseases, thromboembolic diseases and ischaemia, peripheral circulatory disorders, Raynaud's phenomenon, CREST syndrome, micro-circulation disorders, intermittent claudication, and peripheral and autonomic neuropathies.
摘要:
Die Erfindung betrifft Adrenorezeptor α2C Rezeptor Antagonisten zur Verwendung in einem Verfahren zur Behandlung und/oder Prophylaxe von Begleit- und/oder Folgeerkrankungen von Diabetes mellitus, diabetischen Herzerkrankungen, diabetischen koronaren Herzerkrankungen, diabetischen koronaren mikrovaskulären Herzerkrankungen, diabetischer Herzinsuffizienz, diabetischer Kardiomyopathie und Herzinfarkt, diabetischer Mikroangiopathie, diabetischer Retinopathie, diabetischer Neuropathie, diabetischer Nephropathie, diabetischer erektiler Dysfunktion, diabetischen Geschwüren an den Extremitäten, diabetischen Fußulzera, zur Förderung der diabetischen Wundheilung und zur Förderung der Wundheilung von diabetischen Fußulzera.
摘要:
The invention relates to novel substituted bipiperidinyl derivatives, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, especially for promotion of wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulation disorders, Raynaud phenomena, CREST syndrome, microcirculation disorders, intermittent claudication, and peripheral and autonomous neuropathies.
摘要:
The invention relates to novel substituted bipiperidinyl derivatives, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, especially for promotion of wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulation disorders, Raynaud phenomena, CREST syndrome, microcirculation disorders, intermittent claudication, and peripheral and autonomous neuropathies.